Precision Medicine’s Expansion Beyond Oncology
For years, oncology has led the precision medicine revolution. Today, the same biomarker-driven principles are rapidly gaining momentum across neurology, rare disease, I&I disorders and chronic conditions. From multimodal biosignatures and AI-enabled diagnostics, to novel clinical endpoints and next-generation biomarker panels, precision medicine is expanding far beyond its traditional roots.
Recognizing this shift, the 16th World Clinical Biomarkers & Companion Diagnostics Summit will place a stronger emphasis on non-oncology biomarker and IVD innovation in the 2026 agenda.
Highlights Include:
Sickle Cell Disease:
Beam Therapeutics will explore clinical biomarker strategies to support gene editing therapies for sickle cell disease.
MS & Neurodegenerative Diseases:
Novartis are set to share the journey of neurofilament light chain (NfL) as a clinically actionable biomarker in multiple sclerosis and neurodegenerative disorders.
Rare Neurodegenerative Diseases:
Sanford Research will showcase AI-enabled multimodal biosignatures for monitoring rare neurodegenerative diseases.
Rare Disease:
Alexion Pharmaceuticals will open a discussion on how AI-enabled diagnostics can be embedded into routine workflows to scale rare disease testing globally.
Patient Perspectives:
Rare New England will give insight on examining biomarker testing access and policy from the perspective of the rare disease community.
Together, these sessions reflect a broader industry reality: the future of precision medicine will be shaped not only by advances in oncology, but by the development of novel biomarkers and diagnostics capable of transforming care across a much wider range of diseases.
This October, we will explore how those cross-functional and cross-disease learnings can accelerate the development, validation and adoption of novel biomarkers and diagnostics across the full precision medicine landscape.
Explore the New Agenda
Hear the latest imaging, multi-omics, single-cell and functional assays, enhanced by AI-driven digital biomarker strategies, enabling earlier and smarter treatment decisions for oncology, autoimmune, neurological, chronic and rare disease patients
Partner with Us
Position your solutions alongside leading biomarker, diagnostic and technology providers, to ensure your brand is front and center, and retain your place as the partner of choice in the ever-expanding precision medicine space
Join 850+ Specialist Experts
Be part of the liveliest Rx-Dx conversations with like-minded industry peers spanning a range of precision therapy modalities, and build high-value connections during dedicated networking sessions designed to foster collaborations